VANCOUVER, BC / ACCESSWIRE / June 30, 2020 / Canland Health Corp. (formerly, 1155176 B.C. Ltd.) (the “Company”) announces that due to ongoing non-essential business shut down for COVID-19 measures taken by the Province of British Columbia, is exempt from Group A filings and delaying its annual financial statements release and filing on SEDAR until August 13, 2020 (45 day extension).
As required under section 4.2 of BC Instrument 51-515, the Company provides the following updates and information for investors:
About Canland Health Corp.
Canland Health Corp. is in the business of venture capital and investment in the Canadian healthcare sector.
For further information please contact:
Jacky Fu, CFO and director
E-mail: jfu@canlandhc.com
Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based on are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
SOURCE: Canland Health Corp.
View source version on accesswire.com:
https://www.accesswire.com/595756/Canland-Health-Corp-Announces-Extension-of-Filing-Its-Annual-Report-Due-to-COVID-19
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…